니코틴 대체요법 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Nicotine Replacement Therapy Market - Scope of Report

TMR's report on the global nicotine replacement therapy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global nicotine replacement therapy market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global nicotine replacement therapy market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the nicotine replacement therapy market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global nicotine replacement therapy market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global nicotine replacement therapy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global nicotine replacement therapy market.

The report delves into the competitive landscape of the global nicotine replacement therapy market. Key players operating in the global nicotine replacement therapy market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global nicotine replacement therapy market profiled in this report.

Key Questions Answered in Global Nicotine Replacement Therapy Market Report:

• What is the sales/revenue generated by nicotine replacement therapy across all regions during the forecast period?
• What are the opportunities in the global nicotine replacement therapy market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Nicotine Replacement Therapy Market - Research Objectives and Research Approach

The comprehensive report on the global nicotine replacement therapy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global nicotine replacement therapy market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global nicotine replacement therapy market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Nicotine Replacement Therapy Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Nicotine Replacement Therapy Market Analysis and Forecast, 2017-2031
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

• 5.1. Regulatory landscape analysis by key countries
• 5.2. Supply/Value chain analysis
• 5.3. Recent Developments/Latest product launches/Key strategies
• 5.4. Prevalence/Incidence of Smoking Addiction by key regions
• 5.5. Prevalence/Incidence of Individuals Undergoing NRT Therapy by Region
• 5.6. COVID-19 Pandemic Impact on Industry

6. Global Nicotine Replacement Therapy Market Analysis and Forecast, by Product Type

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Product Type, 2017-2031
  • 6.3.1. Smoking Cessation Aids
    • 6.3.1.1. Nicotine Inhalers
    • 6.3.1.2. Nicotine Gums
    • 6.3.1.3. Nicotine Lozenges
    • 6.3.1.4. Nicotine Patches
    • 6.3.1.5. Others
  • 6.3.2. Vaping System
    • 6.3.2.1. E-cigarettes
    • 6.3.2.2. Heat-not-burn Tobacco Products
• 6.4. Market Attractiveness Analysis, by Product Type

7. Global Nicotine Replacement Therapy Market Analysis and Forecast, by Distribution Channel

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 7.3.1. Retail Pharmacies
  • 7.3.2. Hospital Pharmacies
  • 7.3.3. Online Stores
• 7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global Nicotine Replacement Therapy Market Analysis and Forecast, by Region

• 8.1. Key Findings
• 8.2. Market Value Forecast, by Region
  • 8.2.1. North America
  • 8.2.2. Europe
  • 8.2.3. Asia Pacific
  • 8.2.4. Latin America
  • 8.2.5. Middle East & Africa
• 8.3. Market Attractiveness Analysis, by Region

9. North America Nicotine Replacement Therapy Market Analysis and Forecast

• 9.1. Introduction
  • 9.1.1. Key Findings
• 9.2. Market Value Forecast, by Product Type, 2017-2031
  • 9.2.1. Smoking Cessation Aids
    • 9.2.1.1. Nicotine Inhalers
    • 9.2.1.2. Nicotine Gums
    • 9.2.1.3. Nicotine Lozenges
    • 9.2.1.4. Nicotine Patches
    • 9.2.1.5. Others
  • 9.2.2. Vaping System
    • 9.2.2.1. E-cigarettes
    • 9.2.2.2. Heat-not-burn Tobacco Products
• 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 9.3.1. Retail Pharmacies
  • 9.3.2. Hospital Pharmacies
  • 9.3.3. Online Stores
• 9.4. Market Value Forecast, by Country, 2017-2031
  • 9.4.1. U.S.
  • 9.4.2. Canada
• 9.5. Market Attractiveness Analysis
  • 9.5.1. By Product
  • 9.5.2. By Distribution Channel
  • 9.5.3. By Country

10. Europe Nicotine Replacement Therapy Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast, by Product Type, 2017-2031
  • 10.2.1. Smoking Cessation Aids
    • 10.2.1.1. Nicotine Inhalers
    • 10.2.1.2. Nicotine Gums
    • 10.2.1.3. Nicotine Lozenges
    • 10.2.1.4. Nicotine Patches
    • 10.2.1.5. Others
  • 10.2.2. Vaping System
    • 10.2.2.1. E-cigarettes
    • 10.2.2.2. Heat-not-burn Tobacco Products
• 10.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 10.3.1. Retail Pharmacies
  • 10.3.2. Hospital Pharmacies
  • 10.3.3. Online Stores
• 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 10.4.1. Germany
  • 10.4.2. U.K.
  • 10.4.3. France
  • 10.4.4. Italy
  • 10.4.5. Spain
  • 10.4.6. Rest of Europe
• 10.5. Market Attractiveness Analysis
  • 10.5.1. By Product
  • 10.5.2. By Distribution Channel
  • 10.5.3. By Country/Sub-region

11. Asia Pacific Nicotine Replacement Therapy Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Product Type, 2017-2031
  • 11.2.1. Smoking Cessation Aids
    • 11.2.1.1. Nicotine Inhalers
    • 11.2.1.2. Nicotine Gums
    • 11.2.1.3. Nicotine Lozenges
    • 11.2.1.4. Nicotine Patches
    • 11.2.1.5. Others
  • 11.2.2. Vaping System
    • 11.2.2.1. E-cigarettes
    • 11.2.2.2. Heat-not-burn Tobacco Products
• 11.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 11.3.1. Retail Pharmacies
  • 11.3.2. Hospital Pharmacies
  • 11.3.3. Online Stores
• 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.4.1. China
  • 11.4.2. Japan
  • 11.4.3. India
  • 11.4.4. Australia & New Zealand
  • 11.4.5. Rest of Asia Pacific
• 11.5. Market Attractiveness Analysis
  • 11.5.1. By Product
  • 11.5.2. By Distribution Channel
  • 11.5.3. By Country/Sub-region

12. Latin America Nicotine Replacement Therapy Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Product Type, 2017-2031
  • 12.2.1. Smoking Cessation Aids
    • 12.2.1.1. Nicotine Inhalers
    • 12.2.1.2. Nicotine Gums
    • 12.2.1.3. Nicotine Lozenges
    • 12.2.1.4. Nicotine Patches
    • 12.2.1.5. Others
  • 12.2.2. Vaping System
    • 12.2.2.1. E-cigarettes
    • 12.2.2.2. Heat-not-burn Tobacco Products
• 12.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 12.3.1. Retail Pharmacies
  • 12.3.2. Hospital Pharmacies
  • 12.3.3. Online Stores
• 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.4.1. Brazil
  • 12.4.2. Mexico
  • 12.4.3. Rest of Latin America
• 12.5. Market Attractiveness Analysis
  • 12.5.1. By Product
  • 12.5.2. By Distribution Channel
  • 12.5.3. By Country/Sub-region

13. Middle East & Africa Nicotine Replacement Therapy Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Product Type, 2017-2031
  • 13.2.1. Smoking Cessation Aids
    • 13.2.1.1. Nicotine Inhalers
    • 13.2.1.2. Nicotine Gums
    • 13.2.1.3. Nicotine Lozenges
    • 13.2.1.4. Nicotine Patches
    • 13.2.1.5. Others
  • 13.2.2. Vaping System
    • 13.2.2.1. E-cigarettes
    • 13.2.2.2. Heat-not-burn Tobacco Products
• 13.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 13.3.1. Retail Pharmacies
  • 13.3.2. Hospital Pharmacies
  • 13.3.3. Online Stores
• 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.4.1. GCC Countries
  • 13.4.2. South Africa
  • 13.4.3. Rest of Middle East & Africa
• 13.5. Market Attractiveness Analysis
  • 13.5.1. By Product
  • 13.5.2. By Distribution Channel
  • 13.5.3. By Country/Sub-region

14. Competition Landscape

• 14.1. Market Player - Competition Matrix (by tier and size of companies)
• 14.2. Market Share Analysis, by Company, 2022
• 14.3. Company Profiles
  • 14.3.1. Haleon Group of Companies
    • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.1.2. Product Portfolio
    • 14.3.1.3. Financial Overview
    • 14.3.1.4. SWOT Analysis
    • 14.3.1.5. Strategic Overview
  • 14.3.2. Pfizer, Inc.
    • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.2.2. Product Portfolio
    • 14.3.2.3. Financial Overview
    • 14.3.2.4. SWOT Analysis
    • 14.3.2.5. Strategic Overview
  • 14.3.3. McNeil AB (Johnson & Johnson)
    • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.3.2. Product Portfolio
    • 14.3.3.3. Financial Overview
    • 14.3.3.4. SWOT Analysis
    • 14.3.3.5. Strategic Overview
  • 14.3.4. SAABI NZ PTY Limited
    • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.4.2. Product Portfolio
    • 14.3.4.3. Financial Overview
    • 14.3.4.4. SWOT Analysis
    • 14.3.4.5. Strategic Overview
  • 14.3.5. PL Developments
    • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.5.2. Product Portfolio
    • 14.3.5.3. Financial Overview
    • 14.3.5.4. SWOT Analysis
    • 14.3.5.5. Strategic Overview
  • 14.3.6. Cipla Limited
    • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.6.2. Product Portfolio
    • 14.3.6.3. Financial Overview
    • 14.3.6.4. SWOT Analysis
    • 14.3.6.5. Strategic Overview
  • 14.3.7. BAT plc
    • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.7.2. Product Portfolio
    • 14.3.7.3. Financial Overview
    • 14.3.7.4. SWOT Analysis
    • 14.3.7.5. Strategic Overview
  • 14.3.8. JT International SA
    • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.8.2. Product Portfolio
    • 14.3.8.3. Financial Overview
    • 14.3.8.4. SWOT Analysis
    • 14.3.8.5. Strategic Overview
  • 14.3.9. Imperial Brands plc
    • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.9.2. Product Portfolio
    • 14.3.9.3. Financial Overview
    • 14.3.9.4. SWOT Analysis
    • 14.3.9.5. Strategic Overview
  • 14.3.10. Sparsha Pharma International Pvt. Ltd.
    • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.10.2. Product Portfolio
    • 14.3.10.3. Financial Overview
    • 14.3.10.4. SWOT Analysis
    • 14.3.10.5. Strategic Overview
  • 14.3.11. Pierre Fabre S.A.
    • 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.11.2. Product Portfolio
    • 14.3.11.3. Financial Overview
    • 14.3.11.4. SWOT Analysis
    • 14.3.11.5. Strategic Overview
  • 14.3.12. Lucy Goods
    • 14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.12.2. Product Portfolio
    • 14.3.12.2. Financial Overview
    • 14.3.12.3. SWOT Analysis
    • 14.3.12.4. Strategic Overview
  • 14.3.13. Rubicon Research Pvt. Ltd.
    • 14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.13.2. Product Portfolio
    • 14.3.13.3. Financial Overview
    • 14.3.13.4. SWOT Analysis
    • 14.3.13.5. Strategic Overview
  • 14.3.14. JUUL Labs, Inc.
    • 14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.14.2. Product Portfolio
    • 14.3.14.3. Financial Overview
    • 14.3.14.4. SWOT Analysis
    • 14.3.14.5. Strategic Overview
  • 14.3.15. Fontem Holdings 4 B.V.
    • 14.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.15.2. Product Portfolio
    • 14.3.15.3. Financial Overview
    • 14.3.15.4. SWOT Analysis
    • 14.3.15.5. Strategic Overview
  • 14.3.16. Philip Morris International, Inc.
    • 14.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.16.2. Product Portfolio
    • 14.3.16.3. Financial Overview
    • 14.3.16.4. SWOT Analysis
    • 14.3.16.5. Strategic Overview
  • 14.3.17. Perrigo Company plc
    • 14.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.17.2. Product Portfolio
    • 14.3.17.3. Financial Overview
    • 14.3.17.4. SWOT Analysis
    • 14.3.17.5. Strategic Overview